Advanced Search Close Search
WuXi XDC Achieves GMP Release of BCM3 Facility at Singapore Site, Enabling Global Clients with Professional Excellence
Corporate Expansion

WuXi XDC Achieves GMP Release of BCM3 Facility at Singapore Site, Enabling Global Clients with Professional Excellence

  • By WuXi XDC

SINGAPORE, Aug. 18, 2026 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today announced that its BCM3 dual-function production line for antibody intermediates and drug substances of bioconjugates at Singapore site has successfully achieved GMP release. This milestone marks a new phase in the company's global capacity expansion, empowering clients worldwide to accelerate commercial manufacturing with greater efficiency and flexibility in meeting diverse demands.

Licensing Marketing Agreements

Stronger Together, Shaping the Future | WuXi XDC and BioDlink Successfully Concluded 2026 Open Day

  • By BioDlink Biopharm Co., Ltd.

WuXi XDC and BioDlink jointly hosted the 2026 Open Day, marking their first flagship customer-facing event following the strategic integration.The event brought together biotech customers, industry leaders and innovators to explore how an integrated ADC/XDC CRDMO platform can accelerate the development and commercialization of next-generation bioconjugate therapies.